Race- and ethnicity-based disparities in uterine cancer survival vary by geographic locations across the United States.

The Wee1 inhibitor adavosertib shows activity in recurrent uterine serous carcinoma, but the drug’s tolerability remains a ...

Endometrial cancer is the most common gynecological cancer in highly-developed countries, most often affecting women after ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Uterine leiomyosarcoma may be rare, but awareness can save lives. If you or someone you love is experiencing persistent or ...

According to the NHS, symptoms of bowel cancer to look out for include ... anyone with a womb can be diagnosed with uterine cancer. The most obvious symptom is abnormal bleeding from the vagina, but ...

Some symptoms, such as a lump in the breast or ... National Cancer Institute. Uterine cancer-patient version. Sung S, Carlson K, Abramovitz A. Postmenopausal bleeding. In: StatPearls.

Merck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a survival benefit in a confirmatory phase 3 trial.

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

One large-scale study found that about 9% of postmenopausal people who visited their doctor for vaginal bleeding (which is one of the main symptoms of endometrial cancer in older women ...